Weybosset Research & Management LLC trimmed its holdings in shares of Colgate-Palmolive (NYSE:CL) by 1.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 66,264 shares of the company’s stock after selling 1,144 shares during the period. Colgate-Palmolive accounts for about 3.2% of Weybosset Research & Management LLC’s holdings, making the stock its 17th largest holding. Weybosset Research & Management LLC’s holdings in Colgate-Palmolive were worth $4,827,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Blue Chip Partners Inc. lifted its holdings in shares of Colgate-Palmolive by 0.4% in the 2nd quarter. Blue Chip Partners Inc. now owns 1,813 shares of the company’s stock valued at $134,000 after purchasing an additional 8 shares during the last quarter. Cue Financial Group Inc. lifted its holdings in shares of Colgate-Palmolive by 0.3% in the 2nd quarter. Cue Financial Group Inc. now owns 4,854 shares of the company’s stock valued at $360,000 after purchasing an additional 14 shares during the last quarter. M Holdings Securities Inc. lifted its holdings in shares of Colgate-Palmolive by 0.4% in the 1st quarter. M Holdings Securities Inc. now owns 5,366 shares of the company’s stock valued at $393,000 after purchasing an additional 21 shares during the last quarter. AlphaMark Advisors LLC lifted its holdings in shares of Colgate-Palmolive by 1.5% in the 2nd quarter. AlphaMark Advisors LLC now owns 1,698 shares of the company’s stock valued at $126,000 after purchasing an additional 25 shares during the last quarter. Finally, Capital Investment Advisors LLC lifted its holdings in shares of Colgate-Palmolive by 0.3% in the 2nd quarter. Capital Investment Advisors LLC now owns 8,318 shares of the company’s stock valued at $617,000 after purchasing an additional 27 shares during the last quarter. 72.96% of the stock is owned by institutional investors.

Several research firms have recently weighed in on CL. Jefferies Group reissued a “hold” rating and issued a $79.00 target price on shares of Colgate-Palmolive in a report on Thursday, September 28th. Zacks Investment Research downgraded Colgate-Palmolive from a “buy” rating to a “hold” rating in a report on Tuesday, September 26th. Macquarie began coverage on Colgate-Palmolive in a report on Thursday, September 14th. They issued a “neutral” rating and a $76.00 target price for the company. Royal Bank of Canada reissued a “hold” rating and issued a $74.00 target price on shares of Colgate-Palmolive in a report on Sunday, October 8th. Finally, KeyCorp reissued a “hold” rating on shares of Colgate-Palmolive in a report on Saturday, November 25th. Two research analysts have rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $76.04.

Colgate-Palmolive (NYSE:CL) opened at $74.05 on Monday. The company has a debt-to-equity ratio of 24.42, a quick ratio of 0.92 and a current ratio of 1.23. Colgate-Palmolive has a 52-week low of $63.43 and a 52-week high of $77.27. The stock has a market capitalization of $65,023.68, a P/E ratio of 25.80, a price-to-earnings-growth ratio of 3.39 and a beta of 0.81.

Colgate-Palmolive (NYSE:CL) last released its earnings results on Friday, October 27th. The company reported $0.73 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.73. Colgate-Palmolive had a return on equity of 2,782.56% and a net margin of 15.10%. The company had revenue of $3.97 billion for the quarter, compared to analysts’ expectations of $3.94 billion. During the same quarter in the previous year, the firm posted $0.73 EPS. The firm’s quarterly revenue was up 2.8% on a year-over-year basis. sell-side analysts forecast that Colgate-Palmolive will post 2.88 earnings per share for the current fiscal year.

In other Colgate-Palmolive news, Director Stephen I. Sadove sold 20,780 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $70.52, for a total transaction of $1,465,405.60. Following the transaction, the director now owns 36,268 shares in the company, valued at approximately $2,557,619.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Victoria L. Dolan sold 9,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $73.41, for a total value of $660,690.00. The disclosure for this sale can be found here. Insiders have sold a total of 181,048 shares of company stock worth $13,168,995 in the last quarter. 1.02% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: “Colgate-Palmolive (CL) Holdings Cut by Weybosset Research & Management LLC” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/18/colgate-palmolive-cl-holdings-cut-by-weybosset-research-management-llc.html.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company (Colgate) is a consumer products company. The Company operates in two product segments: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care product segment is operated through five geographic segments, which include North America, Latin America, Europe, Asia Pacific and Africa/Eurasia.

Institutional Ownership by Quarter for Colgate-Palmolive (NYSE:CL)

Receive News & Stock Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related stocks with our FREE daily email newsletter.